Introduction
Interleukin 2 (IL-2) is an immunoregulatory cytokine produced by activated T lymphocytes. IL-2 production is considered an index of immune response in vivo. In Jurkat cells, an immortalized human T lymphocyte cell line, IL-2 production can be induced by stimulation with a mitogen such as concanavalin A (ConA) [1] [2] [3] . ConA binds to Tcell receptor, which triggers signaling pathways that lead to the activation of three transcription factors-nuclear factor of activated T cells (NFAT), nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), and activator protein 1 (AP-1, a complex of c-Fos and c-Jun)-which induce the expression of IL-2 mRNA (Fig. 1) [4] [5] [6] [7] .
In T lymphocytes, the immunosuppressive drugs cyclosporine A (CsA) and tacrolimus (FK506) suppress IL-2 production by inhibiting calcineurin (a Ca 2+ /calmodulin-dependent protein serine/threonine phosphatase) via immunophilins, which suppress the activation of NFAT ( Fig. 1 ) [8] [9] [10] . CsA and tacrolimus prevent organ graft rejection and disease progression in patients with rheumatoid arthritis [11] . However, because the clinical use of these and other immunosuppressants (e.g. glucocorticoids) have serious toxicities that affect the renal, nervous, and gastrointestinal systems [12] [13] [14] [15] [16] , novel immunosuppressants with fewer toxicities are needed. D-Glucosamine (GlcNH 2 ) ( Fig. 1A) , a naturally occurring derivative of glucose, possesses various biological and pharmacological activities, including anti-tumor and anti-inflammatory activities [17] [18] [19] [20] [21] [22] [23] [24] [25] . Recently, a novel GlcNH 2 -containing oligosaccharide, Galα1-6GlcNH 2 T (designated melibiosamine; MelNH 2 ) ( Fig. 1A) , was found to exhibit anti-proliferative effects in human leukemia and breast cancer cells in vitro [26, 27] . However, the potential biological and pharmacological activities of MelNH 2 are yet to be fully elucidated.
Here, to assess the potential pharmacological activity and toxicity of MelNH 2 on the immune system, we compared the effects of GlcNH 2 and MelNH 2 on ConA-induced IL-2 production (CIIP) in Jurkat cells. We found that MelNH 2 suppressed CIIP via a mechanism that is, at least in part, different from that through which GlcNH 2 suppresses CIIP, suggesting that MelNH 2 may be a useful lead compound for the development of novel immunosuppressive or anti-inflammatory drugs.
Materials and methods

Cell line and reagents
Jurkat cells were maintained at 37°C (5% CO 2 ) in tissue-culture dishes containing RPMI 1640 growth medium supplemented with 10% (v/v) fetal bovine serum, 25 μg/mL penicillin, and 50 μg/mL streptomycin. MelNH 2 was synthesized as described previously [26] , and GlcNH 2 was purchased from Sigma (St. Louis, MO); these compounds were each dissolved in phosphate-buffered saline (pH 7.4) as 0.1 M solutions, sterilized through a 0.45-μm filter, and stored at −20°C until use. Phorbol 12-myristate 13-acetate (PMA) and ionomycin (IM) were obtained from Sigma, and CsA was purchased from Calbiochem (San Diego, CA), and these compounds were stored as 1, 0.5, and 0.5 mM stock solutions, respectively, in dimethyl sulfoxide (DMSO).
Assay of cell number and viability
Jurkat cells were pre-incubated at 37°C (5% CO 2 ) for 30 min in 0.5 mL RPMI 1640 (1 × 10 6 cells/mL) in a 24-well plate in the presence of 5-20 mM MelNH 2 or GlcNH 2 . Then, ConA was added to each well at a final concentration of 50 μg/mL, and the cells were further incubated at 37°C (5% CO 2 ) for 12 h. After the addition of 0.5 mL trypan blue solution to each well, living and dead cells were counted under a microscope by using a hemocytometer.
Assay of IL-2 production by Jurkat cells
IL-2 production was assessed as described previously with some minor changes [2, 28, 29] . Jurkat cells were pre-incubated at 37°C (5% CO 2 ) for 30 min in 1 mL RPMI 1640 (1 × 10 6 cells/mL) in a 12-well plate in the presence of the indicated concentrations of MelNH 2 or GlcNH 2 or 1 μM CsA. After the addition of ConA (final concentration, 50 μg/mL) or the combination of PMA (1 μM) and IM (0.5 μM), the cells were further incubated at 37°C (5% CO 2 ) for 12 h. Aliquots of the culture media were collected, and the concentration of IL-2 was determined by using a Quantikine Human IL-2 ELISA Kit (R&D Systems, Minneapolis, MN). Briefly, 50-μL aliquots (in duplicate) of the culture media or IL-2 standard from the kit were added to the wells of 96-well plates pre-coated with anti-human IL-2 antibody. After incubation (at 37°C) with biotinylated antibodies against human IL-2 and then with streptavidin-horseradish peroxidase conjugate, color was developed and the level of IL-2 was quantified by measuring absorbance at 450 nm (reference at 570 nm).
Semi-quantitative reverse transcription-polymerase chain reaction assay
Jurkat cells were pre-incubated at 37°C (5% CO 2 ) for 30 min in 1 mL RPMI 1640 (1 × 10 6 cells/mL) in a 12-well plate in the presence or absence of 15 mM GlcNH 2 or MelNH 2 or 5 μM CsA. After the addition of ConA (50 μg/mL), the cells were further incubated at 37°C (5% CO 2 ) for 3 h. Cells were collected by centrifugation (400×g, 5 min), and total RNA was prepared from the cells by using an RNeasy Mini Kit (Qiagen, Hilden, Germany). One microgram of total RNA was reverse transcribed into complementary DNA by using a ReverTra Ace qPCR Kit (Toyobo Co. Ltd., Osaka, Japan), and polymerase chain reaction amplification for IL-2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) complementary DNA was performed as previously described [2, 29] . The following primer pairs were used: IL-2, forward-5′-CAACTCCTGT CTTGCATTGCACTAA-3′, reverse-5′-AATGTGAGCATCCTGGTGAGT TTG-3′; GAPDH, forward-5′-GCACCGTCAAGGCTGAGAAC-3′, reverse-5′-ATGGTGGTGAAGACGCCAGT-3′. 
Preparation of nuclear extracts and transcription factor assay
Jurkat cells were pre-incubated at 37°C (5% CO 2 ) for 30 min in a 10-cm dish in the presence or absence of 5-20 mM GlcNH 2 or MelNH 2 . After the addition of PMA (1 μM) and IM (0.5 μM), or 0.2% DMSO (vehicle), the cells were further incubated at 37°C (5% CO 2 ) for 3 h. After incubation, the cells were collected by centrifugation (200×g, 2 min), lysed with a lysis buffer (in the kit below), and nuclear extracts were prepared by using a Nuclear Extract kit (Active Motif, Carlsbad, CA). After measurement of protein concentrations with a RC-DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA), the nuclear extracts were aliquoted and stored at −80°C until use.
We measured the activation (the contents in nuclear extracts) of NFAT cytoplasmic 1 (NFATc1), NFκB, and phospho-c-Jun by using enzyme-linked immunosorbent assay-based TransAM NFATc1, TransAM NFκB, and TransAM AP-1 c-Jun kits (Active Motif Corp.), respectively. Briefly, nuclear extracts from control and GlcNH 2 -or MelNH 2 -treated cells were incubated in a 96-well plate containing immobilized oligonucleotides (consensus sequences) specific for the particular transcription factor, and bound transcription factor was quantified by enzyme-linked immunosorbent assay.
Results and discussion
Effects of MelNH 2 on IL-2 production and cell viability in Jurkat cells
To assess the potential immunological activity and toxicity of MelNH 2 , we compared the effects of GlcNH 2 and MelNH 2 on CIIP and cell viability in Jurkat cells. As expected from previous reports, the immunosuppressive drug CsA at 1 μM strongly suppressed CIIP [28, 29] , and GlcNH 2 at 2.5-20 mM suppressed CIIP in a dose-dependent manner ( Fig. 2A) [21, 23] . Similarly, MelNH 2 at 2.5-10 mM suppressed CIIP in a dose-dependent manner ( Fig. 2A ). In addition, neither GlcNH 2 nor MelNH 2 at 20 mM or less had any effect on cell number and viability ( Fig. 2C and D) , suggesting that these compounds are not toxic to Jurkat cells.
When administered together to Jurkat cells, PMA and IM mimic the effects of ConA by activating protein kinase C and raising cellular calcium levels, respectively (Fig. 1B) [2, 3] . As expected [28, 29] , CsA at 1 μM strongly suppressed PMA/IM-induced IL-2 production (PIIP), and GlcNH 2 at 2.5-20 mM suppressed PIIP in a dose-dependent manner. In addition, MelNH 2 at 5-10 mM suppressed PIIP (Fig. 2B) .
Next, we examined the effects of GlcNH 2 and MelNH 2 on ConAinduced IL-2 mRNA expression in Jurkat cells (Fig. 3) . As expected, CsA at 1 μM strongly suppressed ConA-induced IL-2 mRNA expression; GlcNH 2 and MelNH 2 at 15 mM also significantly (P < 0.01) suppressed ConA-induced IL-2 mRNA expression.
Together, these results suggest that GlcNH 2 and MelNH 2 both suppress CIIP and PIIP by disrupting the signaling cascade downstream from where PMA and IM exert their actions but upstream of the three transcription factors that regulate IL-2 mRNA expression ( Fig. 1B) .
Effects of MelNH 2 on the activation of NFAT, NFκB, and AP-1 in Jurkat cells
To elucidate the mechanisms underlying the immunosuppressive activities of GlcNH 2 and MelNH 2 , we examined the effects of these compounds on the cytosol-to-nucleus translocation (i.e. the activation) of the three transcription factors that regulate IL-2 expression-NFATc1 (NFAT cytoplasmic 1), NFκB, and AP-1 (Fig. 1B) . GlcNH 2 and MelNH 2 at 5-20 mM both dose-dependently attenuated the activation of NFATc1 and NFκB by PMA/IM (Fig. 4A-D) . However, unlike GlcNH 2 , MelNH 2 at 5-20 dose-dependently promoted the activation of AP-1 by PMA/IM ( Fig. 4E and F) .
These results suggest that MelNH 2 and GlcNH 2 both suppress PIIP (and thus CIIP) by inhibiting the activation of NFATc1 and NFκB.
Comparison of the actions of GlcNH 2 and MelNH 2
We previously reported that GlcNH 2 at 5 mM significantly (P < 0.01) suppressed the growth of human K562 leukemia cells and human HUC-F2 (non-transformed) cells, whereas MelNH 2 at 5 mM significantly (P < 0.01) suppressed the cell growth of K562 cells but not of HUC-F2 cells, as assessed at day 3 after exposure [26] . This suggests that GlcNH 2 is toxic to both tumor cells and non-transformed cells, whereas MelNH 2 is toxic to tumor cells but not to non- transformed cells. In the present study, we found that GlcNH 2 and MelNH 2 at up to 20 mM had no effect on cell number and viability in Jurkat cells, as assessed at hour 12 after exposure ( Fig. 2C and D) , suggesting that the two saccharides are not toxic to mammalian cells, at least within that period of exposure. The present observation that GlcNH 2 suppressed CIIP ( Figs. 2 and 3 ) by, at least in part, inhibiting the activation of NFATc1 and NFκB (Fig. 4A-D) is consistent with a previous observation that GlcNH 2 reduces IL-2 production in mitogen-activated Jurkat cells by inhibiting the NFAT pathway [30] . Interestingly, MelNH 2 , but not GlcNH 2 , promoted the activation of AP-1 by PMA/IM (Figs. 1B and 4E and F) . Although the biological significance of this promotion of AP-1 activation by MelNH 2 is currently unknown, this result suggests that GlcNH 2 and MelNH 2 suppress IL-2 production through different mechanisms; that is, MelNH 2 has two target molecules, one of which is also the target molecule of GlcNH 2 and leads to the inhibition of NFAT and NFκB activation, whereas the other stimulates AP-1 activation. In the near future, we intend to elucidate the target molecule(s) of MelNH 2 in Jurkat cells, which the present results indicate reside downstream from where PMA and IM exert their actions but upstream of the three transcription factors that regulate IL-2 mRNA expression.
Conclusions
The present results suggest that, like GlcNH 2 , MelNH 2 may be a promising lead compound for development as a novel immunosuppressive drug with an improved adverse effect profile compared with those of currently available immunosuppressive drugs.
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